1. Home
  2. ALCYU vs CMMB Comparison

ALCYU vs CMMB Comparison

Compare ALCYU & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALCYU
  • CMMB
  • Stock Information
  • Founded
  • ALCYU N/A
  • CMMB 2004
  • Country
  • ALCYU
  • CMMB Israel
  • Employees
  • ALCYU 3
  • CMMB N/A
  • Industry
  • ALCYU
  • CMMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALCYU
  • CMMB Health Care
  • Exchange
  • ALCYU NYSE
  • CMMB Nasdaq
  • Market Cap
  • ALCYU N/A
  • CMMB 37.3M
  • IPO Year
  • ALCYU N/A
  • CMMB N/A
  • Fundamental
  • Price
  • ALCYU $11.03
  • CMMB $2.01
  • Analyst Decision
  • ALCYU
  • CMMB Strong Buy
  • Analyst Count
  • ALCYU 0
  • CMMB 2
  • Target Price
  • ALCYU N/A
  • CMMB $7.50
  • AVG Volume (30 Days)
  • ALCYU N/A
  • CMMB 81.9K
  • Earning Date
  • ALCYU N/A
  • CMMB 03-06-2025
  • Dividend Yield
  • ALCYU N/A
  • CMMB N/A
  • EPS Growth
  • ALCYU N/A
  • CMMB N/A
  • EPS
  • ALCYU N/A
  • CMMB N/A
  • Revenue
  • ALCYU N/A
  • CMMB N/A
  • Revenue This Year
  • ALCYU N/A
  • CMMB N/A
  • Revenue Next Year
  • ALCYU N/A
  • CMMB N/A
  • P/E Ratio
  • ALCYU N/A
  • CMMB N/A
  • Revenue Growth
  • ALCYU N/A
  • CMMB N/A
  • 52 Week Low
  • ALCYU N/A
  • CMMB $0.55
  • 52 Week High
  • ALCYU N/A
  • CMMB $2.55
  • Technical
  • Relative Strength Index (RSI)
  • ALCYU 50.87
  • CMMB 49.85
  • Support Level
  • ALCYU $11.07
  • CMMB $1.86
  • Resistance Level
  • ALCYU $11.25
  • CMMB $2.15
  • Average True Range (ATR)
  • ALCYU 0.02
  • CMMB 0.14
  • MACD
  • ALCYU -0.00
  • CMMB -0.02
  • Stochastic Oscillator
  • ALCYU 18.52
  • CMMB 45.45

About ALCYU ALCHEMY INVTS ACQUISITION CORP 1 UNIT 1 CL A COM & 1/2 WT

Alchemy Investments Acquisition Corp 1 is a blank check company.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Share on Social Networks: